Characterization of the neutrophil granulocyte epigenomeCharacterization of the T-cell immune response to to various oxidatively modified mycobacterial antigens
Characterization of the neutrophil granulocyte epigenome: Characterization of epigenomic differences in neutrophils from patients with different lung diseases (asthma, COPD, pneumonia, tuberculosis, and viral pulmonary infections such as COVID-19 and influenza) by identifying disease-specific epigenetic and functional signatures
Characterization of the T-cell immune response to to various oxidatively modified mycobacterial antigens: Investigation of the response (activation/stimulation) of antigen-specific T cells from patients with tuberculosis to various oxidatively modified mycobacterial antigens, with the aim of determining whether changes in the redox status of these antigens measurably influence the adaptive immune response.
Study summary
The OXIGENE study is a research project that aims to better understand how the immune system behaves in people with lung diseases such as asthma, COPD, pneumonia, tuberculosis, and viral lung infections. By analyzing a single blood sample, the study examines how certain immune cells react during inflammation and infection, and whether lasting changes in these cells influence how strongly the body responds to disease. Although participants do not receive direct medical benefit, the results may help improve future diagnosis and treatment of lung diseases by providing deeper insight into immune responses.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Diagnosis of an acute or chronic inflammatory lung disease, infectious or non-infectious, including asthma, COPD, pneumonia, tuberculosis, or viral pulmonary infection (e.g., COVID-19, influenza).
* Age ≥ 18 years at the time of informed consent.
* Ability to provide informed consent and consent to the collection and processing of clinical and laboratory data, as well as to the analysis of blood samples as part of study participation.
* Sufficient physical condition to undergo a single venous blood draw (approximately 50 mL), as assessed by the treating physician.
Exclusion Criteria:
* Active malignant disease or ongoing cancer therapy (e.g., chemotherapy or immunotherapy), due to potential immunological confounding.
* Immunosuppressive therapy or known severe immunodeficiency that could interfere with the interpretation of cellular immune responses.
* Pregnancy or breastfeeding, for general research-ethical reasons and to protect vulnerable populations.
* Acute unstable clinical condition that, in the opinion of the treating physician, makes study participation unreasonable.
* Known intolerance to blood sampling or relevant hematological disorders that could compromise the safety or feasibility of venipuncture.
* Lack of capacity to provide informed consent or insufficient understanding of the study content despite supportive explanation.
Primary outcome measure(s)
Characterization of the neutrophil granulocyte epigenome — 2030 Stratification of patients with different lung diseases based on epigenetic signatures of neutrophils: Epigenetics: identification of disease-specific differences in DNA methylation patterns and transcriptional profiles (RNA sequencing).
Characterization of functional signatures — 2030 Stratification of patients with different lung diseases based on functional signatures of neutrophils:
Functional reactivity: quantitative assessment of reactive oxygen species production (oxidative burst) and cellular cell death (e.g., Sytox Green, Annexin V/PI) following stimulation with defined stimuli (e.g., PMA, LPS, Gram-positive/Gram-negative bacteria, BCG, Mycobacterium tuberculosis).
Trial sites (2)
Facility
City
Region
Status
Medical Service Center MVZ, Research Center Borstel, Leibniz Lung Center
Borstel
Schleswig-Holstein
Department of Pulmonology, University Hospital Schleswig-Holstein
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.